RESUMO
Human T-lymphotropic virus type 1 (HTLV-1) is classically associated with the HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP), although the mechanisms of this neurological disorder remain unclear. In addition, some patients who develop "minor" neurological signs that do not meet diagnostic criteria for HAM/TSP are classified as asymptomatic carriers. This study aims to demonstrate the neurological symptoms of Brazilian patients living with HTLV-1 classified as not-HAM.TSP. This observational study evaluated patients treated in an HTLV reference center in Bahia, Brazil, between February 2022 and July 2023. The data were obtained through the analysis of medical records and neurological consultation. Those individuals classified as HAM/ TSP were excluded from this study. 74 patients were submitted to a careful neurological evaluation: 23 HAM/TSP, 22 were classified with intermediate syndrome (IS), and 29 were oligosymptomatic. Self-reported symptoms were significantly more common in the IS group, including urinary symptoms such as nocturia, urgency, incontinence, dysuria, weakness, paresthesia, lumbar pain, xerostomia, and xerophthalmia. Physical examination findings consistent with reduced vibratory and tactile sensitivity were more common in the IS group (p = 0.017 and p = 0.013). Alterations in the V and VIII cranial nerves were present in both groups. HTLV-1 can lead to the development of important neurological signs and symptoms in apparently asymptomatic individuals. This data highlights the need for more research into the neurological aspects of HTLV-1 infection and emphasizes the importance of early diagnosis, treatment, and support for individuals living with this virus.
RESUMO
OBJECTIVE: To determine the prevalence of signs and symptoms of HTLV-1 and 2 infection in paediatric patients. METHODS: We included cohort, case-control and descriptive observational studies that reported the prevalence of signs and symptoms of HTLV-1 and 2 infections in paediatric patients. Searches were performed in MEDLINE® (Ovid), EMBASE and LILACS from inception to the present, and we saturated information with other sources of published and unpublished literature. We decided not to perform meta-analysis according to heterogeneity. RESULTS: A total of eight studies met the inclusion criteria for qualitative analysis. No studies of HTLV-2 were found. Females predominated and there was vertical transmission in nearly 100% of cases. Infective dermatitis was a common manifestation of HTLV in paediatric patients. In addition, persistent hyperreflexia, clonus and the Babinski sign were early neurological alterations observed in patients carrying the virus. CONCLUSION: HTLV screening is recommended in patients presenting infective dermatitis, persistent hyperreflexia, walking disturbances and in those who come from endemic zones.
Assuntos
Dermatite , Infecções por HTLV-I , Vírus Linfotrópico T Tipo 1 Humano , Paraparesia Espástica Tropical , Criança , Feminino , Humanos , Infecções por HTLV-I/epidemiologia , Paraparesia Espástica Tropical/epidemiologia , Reflexo Anormal , Estudos Observacionais como AssuntoRESUMO
The objective of this research was to analyze the impact of the COVID-19 pandemic on seroprevalence of HIV, HBV, HCV and HTLV I-II in donors from a blood bank in Medellin, Colombia, 2019-2022. A cross-sectional analytical study was carried out with three groups: pre-pandemic with 14,879 donors; preventive isolation with 9035; and selective isolation + new normality with 26,647 subjects. Comparisons were made with Chi2 and Bonferroni adjustment, Kruskal-Wallis' H with Dunnett's post-hoc, prevalence ratios, and multivariate logistic regression. COVID-19 decreased donations of men, altruistic and repetitive donors, and increased the age of donors. HIV increased with the COVID-19 pandemic, while HBV, HCV, and HTLV I-II decreased. The pandemic had an independent effect on these viral infections. These findings constitute an alert about what may be happening in the general population and show the importance of improving epidemiological surveillance and the investigation of these infections.
RESUMO
Introducción: Los linfomas gástricos primarios representan menos del 5% de los linfomas no Hodgkin (LNH). La gran mayoría de linfomas gástricos primarios son linfomas de células B de alto grado. Los linfomas gástricos primarios de células T son muy raros y usualmente se asocian a infección por HTLV-1 en regiones endémicas. Material y método. Describimos el caso de una paciente mujer de mediana edad que se presentó con neumoperitoneo debido a ulcera gástrica perforada, síndrome consuntivo y lesiones cutáneas y orales. Resultados. La histopatología e inmunohistoquímica confirmaron linfoma gástrico primario de células T con compromiso cutáneo. La serología para HTLV-1, virus del Epstein-Barr y VIH fueron negativas. Conclusión. La finalidad de este reporte es dar a conocer esta forma de presentación sumamente rara de linfoma gástrico primario.
Background: Primary gastric lymphomas account for less than5%ofnon-Hodgkinlymphomas(NHL).Thevast majority of primary gastric lymphomas are high-grade B-cell lymphomas. Primary gastric T-cell lymphomas are very rare and are usually associated with HTLV-1 infection in endemic regions. We describe Material and methods.the case of a middle-aged female patient who presented with pneumoperitoneum due to a perforated gastric ulcer, wasting syndrome, and skin and oral lesions. . Results: Histopathology and immunohistochemistry confirmed primary gastric T-cell lymphoma with skin involvement. The serologyfor HTLV-1,Epstein-Barr virus and HIVwere negative. The aim of this report is to present Conclusion: this extremely rare presentation of primary gastric lymphoma
RESUMO
Resumen Objetivo: Evaluar la validez del inmunodiagnóstico del htlv i/ii en bancos de sangre, con base en estudios publicados en la literatura científica. Metodología: Se efectuó un metaanálisis de pruebas diagnósticas siguiendo la guía prisma y las recomendaciones de Cochrane. Se evaluó la calidad metodológica con quadas y se garantizó la reproducibilidad y la exhaustividad. Se realizó también un análisis de efectos aleatorios para la sensibilidad, la especificidad, los cocientes de probabilidad, la razón de momios diagnóstica y la curva característica operativa del receptor (roc) con sus intervalos de confianza (ic) del 95 %. Resultados: Se tamizaron 4604 estudios, de los cuales solo tres cumplieron el protocolo. Se evaluaron 548 infectados con htlv i/ii y 6643 sanos. El inmunodiagnóstico de htlv i/ii presentó una sensibilidad del 99 % (ic95 % = 98,0-99,0), especificidad del 100 % (ic95 % = 99,9-100), cocientes de probabilidad positivo de 315,8 (ic95 % = 128,2-778,5) y negativo de 0,02 (ic95 % = 0,01-0,04), razón de momios diagnóstica de 24373 (ic95 % = 6864-86545) y área bajo la curva roc del 99,9 %. Conclusión: Se dispone de pocos estudios en este campo del inmunodiagnóstico htlv i/ii. El elevado número de sujetos analizados evidenció alta validez del inmunodiagnóstico, lo que resulta determinante para garantizar la inocuidad de las unidades de sangre, la detección de portadores asintomáticos, la disminución de la transmisión y el inicio de tratamiento.
Abstract Objective: To evaluate the validity of the immunodiagnosis of htlv i/ii in blood banks, based on studies published in the scientific literature. Methodology: A meta-analysis of diagnostic tests was carried out following the PRISMA guidelines and Cochrane recommendations. The methodological quality was evaluated with QUADAS, and reproducibility and completeness were guaranteed. A random effects analysis was also performed with respect to sensitivity, specificity, likelihood ratios, diagnostic odds ratio, and receiver operating characteristic curve (ROC) with their 95 % confidence intervals (CI). Results: 4,604 studies were screened, of which only three complied with the protocol. 548 subjects infected with HTLV I/II and 6,643 healthy subjects were evaluated. The immunodiagnosis of HTLV I/II had a sensitivity of 99 % (95 % CI = 98.0-99.0), a specificity of 100 % (95 % CI = 99.9-100), a positive likelihood ratio of 315.8 (95 % CI = 128.2-778.5) and a negative likelihood ratio of 0.02 (95 % CI = 0.01-0.04), a diagnostic odds ratio of 24,373 (95 % CI = 6,864-86,545), and an area under the ROC curve of 99.9 %. Conclusion: Few studies are available in the field of HTLV I/II immunodiagnosis. The high number of subjects analyzed showed high validity of the immunodiagnosis, which is decisive to guarantee the safety of the blood units, the detection of asymptomatic carriers, the decrease in transmission, and the start of treatment.
Resumo Objetivo: Avaliar a validade do imunodiagnóstico do HTLV I/II nos bancos de sangue, baseados nos estudos publicados na literatura científica. Metodologia: Foi realizada uma meta-análise de testes diagnósticos seguindo a guia PRISMA e as recomendações de Cochrane. Foi avaliada a qualidade metodológica com QUADAS e garantiu-se a reprodutibilidade e a integridade. Realizou-se também uma análise de efeitos aleatórios para a sensibilidade, a especificidade, os quocientes de probabilidade, a razão de probabilidade diagnóstica e a Curva Característica de Operação do Receptor (Curva ROC) com seus Intervalos de Confiança (IC) de 95%. Resultados: Foram selecionados 4604 estudos, dos quais somente 3 cumpriram com o protocolo. Foram avaliados 548 infectados com o vírus HTLV I/II e 6.643 saudáveis. O imunodiagnóstico de HTLV I/II apresentou uma sensibilidade de 99% (IC95% = 98,0-99,0), especificidade de 100% (IC95%= 99,9-100), quocientes de probalidade positiva de 315,8 (IC95% = 128,2-778,5) e negativo de 0,02 (IC95% = 0,01-0,04), razão de probabilidade diagnóstica de 24373 (IC95% = 6864-86545) e área sob a curva ROC de 99,9%. Conclusão: São poucos os estudos disponíveis neste campo do imunodiagnóstico HTLV I/II. O elevado número de pessoas analisadas evidenciou alta validade do imunodiagnóstico, o que é decisivo para garantir a inocuidade das unidades de sangue, a detecção de portadores assintomáticos, a diminuição da transmissão e o início do tratamento.
RESUMO
RESUMEN Se buscó determinar la prevalencia de marcadores infecciosos en donantes de un banco de sangre en Perú y valorar si las variables sociodemográficas del donante se asocian con la presencia de estos marcadores. Se realizó un estudio transversal analítico en 5942 donantes de un banco de sangre durante el 2018. Se determinó la positividad a inmunodeficiencia humana (VIH), hepatitis B (VHB), hepatitis C (VHC) y HTLV I-II; además de sífilis y enfermedad de Chagas. La prevalencia de VIH fue 0,81%, VHB 6,19%, VHC 0,12%, HTLV I-II 0,66%, enfermedad de Chagas 2,76% y sífilis 1,73%. Diversos factores sociodemográficos se asociaron con la positividad de marcadores infecciosos. El tipo de donación predominante fue no voluntaria (96%) y el 53% presentó historia de donación previa. Las prevalencias de marcadores infecciosos de VIH, VHB, enfermedad de Chagas y sífilis en los donantes de sangre fueron altas comparadas con otros países de la región.
ABSTRACT We aimed to determine the prevalence of infection markers in donors of a Peruvian blood bank and to assess whether donor sociodemographic variables are associated with the presence of these markers. An analytical cross-sectional study was carried out in 5942 donors of a blood bank, whose data was collected during 2018. Positivity to human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV) and HTLV I-II was determined, in addition to syphilis and Chagas disease. The prevalence of HIV was 0.81%; for HBV it was 6.19%; for HCV, 0.12%; for HTLV I-II, 0.66%; for Chagas disease, 2.76% and for syphilis it was 1.73%. Several sociodemographic factors were associated with infection markers positivity. The predominant donation type was non-voluntary (96%) and 53% had history of previous donation. The prevalence of infection markers for HIV, HBV, Chagas disease and syphilis in blood donors was high compared to other countries in the region.
Assuntos
Bancos de Sangue , Doadores de Sangue , Prevalência , Vírus Linfotrópico T Tipo 2 Humano , Sífilis , HIV , Hepatite C , Doença de Chagas , Hepatite BRESUMO
Introdução: Vírus Linfotrópico de Células T Humana do Tipo-1 (HTLV-1) é um retrovírus que afeta os linfócitos T humano e desencadeia inflamação na medula, levando à paraparesia espástica tropical/mielopatia associada ao HTLV-1 (PET/MAH) com prejuízos funcionais. Tais disfunções podem influenciar nos efeitos da fisioterapia, gerando diferentes níveis de fadiga. Objetivo: Avaliar a percepção subjetiva de esforço e de recuperação de indivíduos com PET/MAH após sessão única de fisioterapia. Métodos: Incluíram-se 12 participantes sintomáticos para PET/MAH, de ambos os sexos, que foram submetidos uma vez ao protocolo fisioterapêutico. Os instrumentos avaliativos foram: Escala Modificada de Borg, Escala de Percepção Subjetiva de Recuperação (1º, 5º e 10º minuto após a sessão) e Escala de Incapacidade Neurológica do Instituto de Pesquisa Clínica Evandro Chagas 2 (EIPEC). Resultados: Encontrou-se correlação moderada entre idade e taxa de percepção subjetiva de recuperação ao 1º (r = - 0,4923) e 5º (r = - 0,4913) minuto e entre índice do EIPEC-2 e taxa de percepção subjetiva de recuperação ao 1º (r = 0,3592) e 5º (r = - 0,3772) minuto. Conclusão: Indivíduos deste estudo com maior idade e grau de incapacidade neurológica têm menor percepção subjetiva de recuperação. (AU)
Introduction: Human T-Cell Lymphotropic Virus Type-1 (HTLV-1) is a retrovirus that affects human T lymphocytes and triggers inflammation in the spinal cord, leading to tropical spastic paraparesis / HTLV-1 associated myelopathy (TSP/HAM) with functional impairments. Such dysfunctions can influence the effects of physical therapy, generating different levels of fatigue. Objective: To evaluate the subjective perception of effort and recovery of individuals with TSP/HAM after a single session of physical therapy. Methods: 12 symptomatic participants for TSP/HAM, of both sexes, who were submitted once to a physiotherapeutic protocol were included. The evaluative instruments were: Modified Borg Scale, Scale of Subjective Perception of Recovery (1st, 5th and 10th minute after the session) and Scale of Neurological Disability at the Evandro Chagas Clinical Research Institute - 2 (EIPEC). Results: A moderate correlation was found between age and subjective perception rate of recovery at the 1st (r = - 0.4923) and 5th (r = - 0.4913) minute and between the EIPEC-2 index and the subjective perception rate of recovery at the 1st (r = 0.3592) and 5th (r = - 0.3772) minute. Conclusion: Individuals in this study with older age and degree of neurological disability have less subjective perception of recovery. (AU)
Assuntos
Humanos , Paraparesia Espástica Tropical , Modalidades de Fisioterapia , Fadiga , Exercício Físico , Vírus Linfotrópico T Tipo 1 HumanoRESUMO
In individuals with HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP), spasticity is one of the main symptoms. The neurological signs of the disease are well defined, but details of how spasticity appears in these individuals have not been well explored. To describe spasticity location and severity of HAM/TSP individuals. Cross-sectional study with individuals older than 18 years, diagnosed with HAM/TSP and with lower limb spasticity. Pregnant women, individuals with other associated neurological diseases, and those using antispastic drugs were not included. Spasticity was assessed by the Modified Ashworth Scale (MAS), applied to the abductor, adductor, flexor, and extensor muscles of the hips, flexors, and extensors of the knees, dorsiflexors, plantiflexors, evertors, and inverters of the foot. Thirty participants were included. The plantiflexor muscles (90%), knee extensors (80%), knee flexors (63,3%), and adductors (50%) were most frequently affected by spasticity. Twenty-three (76.7%) individuals had mixed spasticity, 5 (16.7%) with distal spasticity and 2 (6.7%) with proximal spasticity. MAS was similar between the lower limbs in at least 6 of the 10 muscle groups of each individual. Spasticity was mostly mixed in the lower limbs, with more frequently mild severity. The individuals were partially symmetrical between the lower limbs. The most affected muscle groups were the plantiflexors, knee extensors and flexors and the hip adductors, consecutively, being predominantly symmetrical.
Assuntos
Paraparesia Espástica Tropical , Estudos Transversais , Feminino , Humanos , Espasticidade Muscular/diagnóstico , Músculo Esquelético , Paraparesia Espástica Tropical/complicações , Paraparesia Espástica Tropical/diagnóstico , GravidezRESUMO
Resumen Antecedentes: El virus linfotrópico T tipo I (HTLV-I) origina la paraparesia espástica tropical (PET) en el 3% de los infectados, afectando predominante mujeres. Excepcionalmente la PET puede asociar un síndrome vestibular central y atrofia cerebelosa. Propósito: Presentar un nuevo y excepcional caso de paraparesia espástica y atrofia cerebelosa. Sugerir una interpretación patogénica del predominio femenino en esta patología Paciente: Mujer de 20 años de talla baja y menuda, infectada con HTLV-I durante la lactancia. Aproximadamente a los 15 años inició un síndrome ataxo-espástico progresivo, con grave alteración de la marcha, posteriormente agregó daño cognitivo y atrofia cerebelosa en la RM. Se constató a su ingreso una elevada carga viral y altos niveles de proteína Tax. Fue tratada con 4 mg betametasona diarios durante 10 días, que mejoraron la marcha. Conclusión: La PET es una axonopatía de la vía motora central, originada por la crónica perturbación del transporte axoplásmico, atribuible a la presencia de elevados niveles de la proteína Tax del virus. Circunstancialmente este aumento de Tax logra dañar axones del centro oval (deterioro cognitivo) o del vermis cerebeloso (síndrome vestibular central). La PET afecta mayoritariamente a mujeres 3:1, prevalencia que hace aparecer a las mujeres con una mayor vulnerabilidad en su SNC. Sin embargo, esta aparente minusvalía, sería debida a un aumento en la concentración de Tax en el SNC de ellas, causado por la adversa relación entre peso corporal y cantidad absoluta de Tax, que fue evidente en nuestra paciente, quien dio la clave para esta hipótesis.
Background: Lymphotropic Virus Type I (HTLV-I) causes Tropical Spastic Paraparesis (PET) in 3% of infected patients; in whom have been described exceptionally associated a central vestibular syndrome and cerebellar atrophy. Those alterations of CNS are predominating in women. Purpose: To present a new case of the exceptional form of spastic paraparesis and cerebellar atrophy. To suggest a pathogenic interpretation of female predominance in this pathology Patient: A 20-year-old woman of small size, infected with HTLV-I during lactation. Approximately at 15 years of age he started a progressive ataxo-spastic syndrome, later cognitive damage and cerebellar atrophy were added. Upon admission, high viral load and high levels of Tax protein, leukemoid lymphocytes and Sicca syndrome were observed. Conclusion: PET is an axonopathy of the central motor pathway, originated by a chronic disturbance of axoplasmic transport, attributable to the action of elevated levels of Tax protein in the CNS. In addition axons of the oval center (cognitive impairment) or the cerebellar vermis (central vestibular syndrome) are occasionally damaged. Although PET mainly affects 3: 1 women, this prevalence increases in accordance with the increase of neurological damage. The apparent greater vulnerability of the CNS in women would be due to the higher concentration of Tax in the CNS of them, originated in the adverse relationship between body weight and absolute amount of Tax, which was evident in our patient, who gave the key to this hypothesis.
Assuntos
Humanos , Feminino , Adulto , Atrofia , Axônios , Síndrome , Vírus Linfotrópico T Tipo 1 Humano , Paraparesia Espástica TropicalRESUMO
This was a cross-sectional prospective study. We performed a multivariate statistical analysis of the neurological signs and symptoms of patients infected with human T cell lymphotropic virus type 1 (HTLV-1) in an attempt to separate them into distinct groups and identify clinical-neurological manifestations that could differentiate the various profiles. The study was performed in the city of Belém (state of Pará), located in the Amazon region of Brazil, from 2014 to 2016. We determined muscle strength and tone, reflexes, sensations, sphincter function, gait, and the Expanded Disability Status Scale score among individuals with HTLV-I. We then used exploratory statistical methods in an attempt to find different profiles and establish distinct groups. We analyzed 60 patients with HTLV-1. The filtering of the data, performed with mixed PCA, gave rise to a streamlined database with the most informative data and suggested the formation of three statistically distinct groups: asymptomatic carriers (AC), mono/oligosymptomatic (MOS), and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSPd), AC and MOS (p = 0.002), AC and HAM/TSPd (p < 0.001), and HAM/TSPd and MOS (p = 0.001). The subsequent cluster analysis confirmed the formation of three clusters. The classification and regression tree demonstrated that altered gait was the most important variable for the classification of an individual with HAM/TSPd and that, in the absence of this impairment, hyperreflexia characterized MOS. The present study was able to separate patients infected by HTLV-1 into three clinical groups (AC, HAM/TSPd, and MOS) and identify clinical manifestations that could differentiate the various patient groups.
Assuntos
Vírus Linfotrópico T Tipo 1 Humano/patogenicidade , Paraparesia Espástica Tropical/diagnóstico , Paraparesia Espástica Tropical/fisiopatologia , Reflexo Anormal , Adulto , Doenças Assintomáticas , Análise por Conglomerados , Estudos Transversais , Avaliação da Deficiência , Feminino , Marcha/fisiologia , Vírus Linfotrópico T Tipo 1 Humano/fisiologia , Humanos , Masculino , Pessoa de Meia-Idade , Força Muscular/fisiologia , Paraparesia Espástica Tropical/classificação , Paraparesia Espástica Tropical/virologia , Análise de Componente Principal , Estudos Prospectivos , Índice de Gravidade de DoençaRESUMO
Abstract INTRODUCTION: Studies have linked human T-cell lymphotropic virus type-1 (HTLV-1) to psychiatric disease. METHODS: Patients with HTLV-1 were compared to patients seen by family doctors using a semi-structured questionnaire and the Hospital Anxiety and Depression Scale. RESULTS: Participants with (n=58) and without (n=340) HTLV were compared. Anxiety and depression were associated with greater age, being a woman, spastic paraparesis (depression: PR=4.50, 95% CI: 3.10-6.53; anxiety: PR=2.96, 95% CI: 2.08-4.21), and asymptomatic HTLV (depression: PR=4.34, 95% CI: 3.02-6.24; anxiety: PR=2.81, 95% CI: 2.06-3.85). CONCLUSIONS: Symptomatic and asymptomatic patients with HTLV-1 experienced more anxiety and depression than uninfected patients.
Assuntos
Humanos , Masculino , Feminino , Adulto , Transtornos de Ansiedade/etiologia , Infecções por HTLV-I/complicações , Transtorno Depressivo/etiologia , Transtornos de Ansiedade/psicologia , Infecções por HTLV-I/psicologia , Estudos de Casos e Controles , Estudos Transversais , Inquéritos e Questionários , Transtorno Depressivo/psicologia , EscolaridadeRESUMO
A estrongiloidíase é uma enfermidade que acomete cerca de 100 milhões de pessoas em todo mundo. Essa parasitose apresenta alta prevalência e tem maior gravidade clínica entre indivíduos imunossuprimidos, principalmente aqueles portadores do vírus linfotrópico de células T humana tipo 1 (HTLV). Este fato torna a coinfecção por esse vírus em pacientes parasitados por Strongyloides stercoralis um grave problema de saúde pública. O presente estudo teve por objetivo revisar os estudos sobre coinfecção por HTLV/S. stercoralis. Foi realizada busca eletrônica completa de dados disponíveis sobre a coinfecção entre o vírus e S. stercoralis. As publicações foram capturadas a partir das bases de dados PubMed e SciELO, sendo utilizados os seguintes descritores "vírus linfotrópico de células T humanas tipo 1", "HTLV-1", "S. stercoralis" e "estrongiloidiase". A infecção por HTLV em pacientes parasitados representa fator de risco para o desenvolvimento de estrongiloidíase grave e, nesses indivíduos, o tratamento recomendado deve ser realizado e monitorado para garantir o sucesso terapêutico.(AU)
Strongyloidiasis is a disease that affects approximately 100 million people worldwide. This parasitosis is highly prevalent and more clinically severe among immunosuppressed individuals, particularly those with Human T-lymphotropic virus 1 (HTLV-1). This fact makes the co-infection with this virus in patients parasitized by Strongyloides stercoralis a serious public health problem. The present study aimed at reviewing the studies of co-infection with HTLV/S. stercoralis. A complete electronic search for available data about the co-infection of the virusand S. stercoralis was performed. The publications were obtained from the databases PubMed and SciELO, with the following descriptors being used: "Human T-lymphotropic Virus type 1, "HTLV-1", S. stercoralis, and "strongyloidiasis". The infection with HTLV in infected patients is a risk factor for the development of severe strongyloidiasis, and for these individuals the recommended treatment should be performed and monitored to ensure therapeutic success.(AU)
Assuntos
Humanos , Masculino , Feminino , Infecções por HTLV-I/tratamento farmacológico , Vírus Linfotrópico T Tipo 1 Humano , Paraparesia Espástica Tropical , Strongyloides stercoralis/parasitologia , Estrongiloidíase/parasitologiaRESUMO
Strongyloides stercoralis infection in patients with HTLV-I infection may lead to severe clinical manifestations. The aim of the present study is to determine the seroprevalence of S. stercoralis infection among blood donors who tested positive for HTLV-I infection. A cross-sectional study was performed at the Vall d'Hebron University Hospital (Barcelona, Spain) in 2016. Serum samples from HTLV-I positive patients diagnosed from 2008 to 2015 were retrieved from the Blood Bank, and S. stercoralis serology was performed. Thirty six serum samples from HTLV-I positive patients were retrieved from the Blood Bank. The blood samples came from 36 blood donors, and most of them were born in Latin America (75%), being Peru the most frequent country (11 participants). S. stercoralis serology was positive in one patient, corresponding to a prevalence of 2.8% (3.4% if we exclude donors coming from European countries, where the risk of S. stercoralis infection is highly unlikely).
Assuntos
Anticorpos Anti-Helmínticos/sangue , Doadores de Sangue , Infecções por HTLV-I/complicações , Strongyloides stercoralis/imunologia , Estrongiloidíase/sangue , Estrongiloidíase/epidemiologia , Adolescente , Adulto , Idoso , Animais , Estudos Transversais , Feminino , Humanos , América Latina/etnologia , Masculino , Pessoa de Meia-Idade , Peru/etnologia , Prevalência , Estudos Soroepidemiológicos , Espanha/epidemiologia , Estrongiloidíase/complicações , Adulto JovemRESUMO
The human T-lymphotropic virus type-1 (HTLV-1) is the causative agent of adult T cell leukemia/lymphoma (ATL) and HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP). CD4+T cells are the main target of HTLV-1, but other cell types are known to be infected, including immature lymphocytes. Developing T cells undergo differentiation in the thymus, through migration and interaction with the thymic microenvironment, in particular with thymic epithelial cells (TEC) the major component of this three dimensional meshwork of non-lymphoid cells. Herein, we show that TEC express the receptors for HTLV-1 and can be infected by this virus through cell-cell contact and by cell-free virus suspensions. The expression of anti-apoptosis, chemokine and adhesion molecules genes are altered in HTLV-1-infected TEC, although gene expression of antigen presentation molecules remained unchanged. Furthermore, HTLV-1-infected TEC transmitted the virus to a CD4+ T cell line and to CD4+ T cells from healthy donors, during in vitro cellular co-cultures. Altogether, our data point to the possibility that the human thymic epithelial cells play a role in the establishment and progression of HTLV-1 infection, functioning as a reservoir and transmitting the virus to maturing CD4+ T lymphocytes, which in turn will cause disease in the periphery.
Assuntos
Linfócitos T CD4-Positivos/fisiologia , Células Epiteliais/virologia , Infecções por HTLV-I/transmissão , Vírus Linfotrópico T Tipo 1 Humano/fisiologia , Timo/patologia , Apoptose/genética , Linfócitos T CD4-Positivos/virologia , Moléculas de Adesão Celular/genética , Moléculas de Adesão Celular/metabolismo , Linhagem Celular , Quimiocinas/genética , Quimiocinas/metabolismo , Técnicas de Cocultura , Progressão da Doença , Células Epiteliais/fisiologia , Regulação da Expressão Gênica , Infecções por HTLV-I/imunologia , Humanos , Leucemia-Linfoma de Células T do Adulto , Paraparesia Espástica , Paraparesia Espástica Tropical , Receptores Virais/metabolismo , Internalização do VírusRESUMO
RESUMEN El virus linfotrópico humano tipo 1 (HTLV-1) genera trastornos como la mielopatía inflamatoria crónica y progresiva conocida como mielopatía asociada al HTLV-1 (MAH), caracterizada por un cuadro clínico de paraparesia espástica. Inicialmente, el virus fue reportado en zonas tropicales y actualmente está presente en diferentes regiones del mundo. El HTLV-1 se puede transmitir tanto horizontal como verticalmente y permanecer latente en los pacientes; se calcula que de 1 % a 5 % de los infectados desarrollan leucemia/linfoma de células T en el adulto (LTA) y de 3 % a 5 %, MAH. Esta revisión, por medio de la búsqueda sistemática en bases de datos, es una compilación de la información más sobresaliente acerca de este retrovirus y la paraparesia espástica, aporta al conocimiento básico de la enfermedad, difunde un problema de salud poco conocido y genera la necesidad de hacer un diagnóstico temprano a fin de intervenir en la cadena de transmisión del virus y evitar su propagación silenciosa en la población.
SUMMARY Human T-lymphotropic virus type 1 (HTLV-1) causes disorders such as chronic inflammatory progressive myelopathy, which is known as HTLV-1associated myelopathy (MAH), characterized by spastic paraparesis symptoms. Originally, the virus was reported in tropical zones and is currently distributed in different regions of the world. HTLV-1 can be transmitted both horizontally and vertically, and remains latent in patients; between 1 % and 5 % of those infected develop adult T cell leukemia/lymphoma (LTA) and 3 % to 5 %, MAH. This review, carried out through systematic search of databases, compiles the most outstanding information about this retrovirus and the spastic paraparesis, provides basic knowledge on the disease, illustrates on an unknown health problem and creates the need for early diagnosis in order to stop the chain of viral infection and prevent its silent propagation among the population.
RESUMO O vírus linfotrópico humano tipo 1 (HTLV-1) gera transtornos como a mielopatia inflamatória crônica e progressiva conhecida como mielopatia associada ao HTLV-1 (MAH), caracterizada por um quadro clínico de paraparesia espástica. Inicialmente, o vírus foi reportado em zonas tropicais e atualmente está presente em diferentes regiões do mundo. O HTLV-1 se pode transmitir tanto horizontal como verticalmente e permanecer latente nos pacientes; calculase que de 1% a 5% dos infectados desenvolvem leucemia/linfoma de células T no adulto (LTA) e de 3% a 5%, MAH. Esta revisão, por meio da pesquisa sistemática em bases de dados, é uma compilação da informação mais sobressalente sobre este retrovírus e a paraparesia espástica, aporta ao conhecimento básico da doença, difunde um problema de saúde pouco conhecido e gera a necessidade de fazer um diagnóstico precoce com o fim de intervir na cadeia de transmissão do vírus e evitar a sua propagação silenciosa na população.
Assuntos
Humanos , Vírus Linfotrópico T Tipo 1 Humano , Revisão , Paraparesia Espástica , Paraparesia Espástica Tropical , DiagnósticoRESUMO
Human T-lymphotropic virus 1 (HTLV-1) is the etiologic agent of the HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Apoptosis is a mechanism of defense elicited by many triggers, including cross-linking of the FAS receptor expressed in viruses-infected cells, and the ligand FASL presented by T-cytotoxic cells. As HAM/TSP has been associated with high levels of proviral load (PVL), we hypothesized that certain genotypes of single-nucleotide polymorphisms (SNPs) associated with a decreased protein expression of FAS and FASL could be risk factors for this disease. Three SNPs: FAS-670A/G (rs1800682), FAS-1377G/A (rs2234767), and FASL-844C/T (rs763110) were analyzed in 73 HAM/TSP patients and 143 HTLV-1 asymptomatic carriers. Ancestry informative markers were used to adjust for ethnicity through a principal component analysis. Gender, age, PVL, and the first three principal components were used as covariates. The FAS/FASL genotype distribution was not associated with HAM/TSP presence (P-> 0.05). The FAS-670 AA genotype was associated with high PVL in comparison to FAS-670 GG in HAM/TSP patients (P = 0.015), while in asymptomatic carriers low levels of PVL were observed (P > 0.05). Our findings suggest that rs1800682, rs2234767, and rs763110 genotypes are not associated with the presence of HAM/TSP, but that the FAS-670 AA genotype can promote higher PVL values in HAM/TSP patients. J. Med. Virol. 89:726-731, 2017. © 2016 Wiley Periodicals, Inc.
Assuntos
Genótipo , Infecções por HTLV-I/virologia , Polimorfismo de Nucleotídeo Único , Provírus/genética , Carga Viral , Receptor fas/genética , Estudos de Coortes , Feminino , Humanos , Masculino , Pessoa de Meia-IdadeRESUMO
ABSTRACT Clinical and laboratory parameters including blood and cerebrospinal fluid (CSF) neopterin were investigated in human-T-lymphotropic-virus-type-I associated-myelopathy/tropical-spastic-paraparesis-HAM/TSP and in HTLV-I carriers. HAM/TSP (n = 11, 2 males/9 females, median age = 48 years), recently diagnosed HTLV-I carriers (n = 21, 15 females/6 males, median age = 44 years), healthy individuals (n = 20, 10 males/10 females, median age = 34.6 years) from the Brazilian Amazon (Manaus, Amazonas State) were investigated. Neopterin was measured (IBL ELISA Neopterin, Germany) in serum samples of all the participants, in CSF of 9 HAM/TSP patients as well as in 6 carriers. In HAM/TSP patients, CSF cell counts, protein and glucose were measured, the Osame’s motor-disability-score/OMDS was determined, and brain/spinal cord magnetic-resonance-imaging (MRI) was performed. HAM/TSP patients had normal CSF glucose, leukocyte counts; and normal protein levels predominated. Brain-MRI showed white-matter lesions in 7 out of 11 HAM/TSP patients. OMDS varied from 2-8: 9 were able to walk, 2 were wheel-chair-users. The median serum neopterin concentration in HAM/TSP patients was 6.6 nmol/ L; min. 2.8- max. 12.5 nmol/ L); was lower in carriers (4.3 nmol/L; min. 2.7- max. 7.2 nmol/ L) as well as in healthy participants (4.7 nmol/ L; min. 2.7- max. 8.0 nmol/ L) (p < 0.05). CSF neopterin concentrations in HAM/TSP patients were higher than in serum samples, and higher compared to carriers (p < 0.05). Carriers had similar serum-CSF neopterin concentrations compared to healthy participants. Variable clinical and laboratory profiles were seen in HAM/TSP patients, however our results support the neopterin measurement as a potential biomarker of disease activity.
Assuntos
Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Idoso , Vírus Linfotrópico T Tipo 1 Humano , Neopterina/sangue , Neopterina/líquido cefalorraquidiano , Paraparesia Espástica Tropical/sangue , Paraparesia Espástica Tropical/líquido cefalorraquidiano , Biomarcadores/sangue , Biomarcadores/líquido cefalorraquidiano , Brasil , Portador Sadio , Estudos de Casos e Controles , Imageamento por Ressonância MagnéticaRESUMO
INTRODUCTION: Human lymphotropic virus (HTLV I/II) is a retrovirus that is prevalent across the Colombian Pacific coast, and is potentially transmissible by transfusion. Blood bank screening has been regulated since 2004, in order to reduce transmission of HTLV I/II through donation. Information on the seroprevalence of the virus in southwestern Colombia is limited. OBJECTIVE: To determine the seroprevalence and the behavior of reactivity to HTLV I/II before and after the introduction of Western blot, and the comorbidity of HTLV and other infectious markers in donors from a blood bank in Cali, Colombia. MATERIALS AND METHODS: We conducted a cross-sectional study of 77,117 blood bank donors from the Fundación Valle del Lili by analyzing records of donors who had been tested with the reactive test for anti-HTLV I-II antibodies (IgG) between January, 2008, and December, 2014. RESULTS: The cumulative seroprevalence during the study period was 0.24% (186/77,119). Reactivity was more common in women (61%), and the median age was 37 years (IQR: 24-48). The seroprevalence in the years before the introduction of Western blot was 0.13%, 0.19%, 0.31%, 0.32% and 0.18% (2008-2012), and thereafter it was 0.08% and 0.07% (2012-2014). Concomitant reactivity with other infectious markers was 11%: syphilis (57%), followed by HIV (19%), hepatitis B (14%) and hepatitis C (9%). The highest seroprevalence (0.38%) was reported in 2012. CONCLUSION: We found a high prevalence of reactivity to HTLV I-II compared to that reported in other studies. The results of this study are a starting point for the development of population studies.
Assuntos
Anticorpos Antivirais/sangue , Doadores de Sangue , Transmissão de Doença Infecciosa/estatística & dados numéricos , Hepatite B/sangue , Bancos de Sangue , Transfusão de Sangue , Western Blotting , Colômbia , Estudos Transversais , Hepatite B/transmissão , Humanos , Prevalência , Estudos SoroepidemiológicosRESUMO
Introducción. El virus linfotrópico humano (HTLV) de tipos I y II es un retrovirus prevalente en la Costa Pacífica colombiana que puede transmitirse por transfusiones de sangre. En el 2014 se reglamentó la tamización para bancos de sangre con el fin de reducir la transmisión por medio de la donación. La información sobre la seroprevalencia del virus en el suroccidente colombiano es limitada. Objetivo. Determinar la seroprevalencia, el comportamiento a lo largo del tiempo de los resultados reactivos antes y después de la introducción del inmunoensayo Western blot y la concomitancia del HTLV con otros marcadores de infección en donantes de un banco de sangre de Cali, Colombia. Materiales y métodos. Se hizo un estudio trasversal de 77.117 donantes del Banco de Sangre de la Fundación Valle del Lili mediante el análisis de los registros de donantes con prueba reactiva para anticuerpos IgG anti HTLV I-II entre enero de 2008 y diciembre de 2014. Resultados. La seroprevalencia acumulada fue de 0,24 %. Los resultados reactivos fueron más frecuentes en mujeres (61 %) y la mediana de edad fue de 37 años. La seroprevalencia en los años previos a la introducción del Western blot fue de 0,13, 0,19, 0,31 y 0,32 % (2008-2012), y posteriormente fue de 0,18, 0,08 y 0,07 % (2012-2014). La reacción positiva concomitante con otros marcadores de infección fue de 11 %: sífilis (57 %), HIV (19 %), hepatitis B (14 %) y hepatitis C (9 %). La mayor seroprevalencia (0,38 %) se registró en el 2012. Conclusión. Se encontró una alta prevalencia de pruebas reactivas para el HTLV I-II en comparación con otros estudios. Los resultados de este estudio son un punto de partida para el desarrollo de estudios poblacionales.
Introduction: Human lymphotropic virus (HTLV I/II) is a retrovirus that is prevalent across the Colombian Pacific coast, and is potentially transmissible by transfusion. Blood bank screening has been regulated since 2004, in order to reduce transmission of HTLV I/II through donation. Information on the seroprevalence of the virus in southwestern Colombia is limited. Objective: To determine the seroprevalence and the behavior of reactivity to HTLV I/II before and after the introduction of Western blot, and the comorbidity of HTLV and other infectious markers in donors from a blood bank in Cali, Colombia. Materials and methods: We conducted a cross-sectional study of 77,117 blood bank donors from the Fundación Valle del Lili by analyzing records of donors who had been tested with the reactive test for anti-HTLV I-II antibodies (IgG) between January, 2008, and December, 2014. Results: The cumulative seroprevalence during the study period was 0.24% (186/77,119). Reactivity was more common in women (61%), and the median age was 37 years (IQR: 24-48). The seroprevalence in the years before the introduction of Western blot was 0.13%, 0.19%, 0.31%, 0.32% and 0.18% (2008-2012), and thereafter it was 0.08% and 0.07% (2012-2014). Concomitant reactivity with other infectious markers was 11%: syphilis (57%), followed by HIV (19%), hepatitis B (14%) and hepatitis C (9%). The highest seroprevalence (0.38%) was reported in 2012. Conclusion: We found a high prevalence of reactivity to HTLV I-II compared to that reported in other studies. The results of this study are a starting point for the development of population studies.
Assuntos
Anticorpos Anti-HTLV-I , Anticorpos Anti-HTLV-II , Doadores de Sangue , Western Blotting , Prevalência , SorologiaRESUMO
Para determinar la prevalencia de enteroparásitos en individuos seropositivos a los virus HTLV-I/II, se seleccionaron aleatoriamente 75 donantes que asistieron a los Bancos de Sangre de dos instituciones sanitarias del municipio Maracaibo, Venezuela. Se contactaron personalmente 50 individuos seropositivos a virus HTLV-I/II (grupo muestra) y 25 seronegativos (grupo control), quienes aportaron una muestra fecal para diagnóstico parasitológico. Estas fueron sometidas al examen al fresco con solución salina fisiológica (SSF) al 0,85%, tinción temporal de Lugol y técnica de concentración con formol-éter (Ritchie). Además se realizó cultivo en Agar Nutritivo (método de Arakaki) para investigar la presencia de larvas de Strongyloides stercoralis. Se determinó una prevalencia general de enteroparásitos en el grupo muestra de 54% y 44% en el grupo control. Predominó el monoparasitismo entre todos los individuos estudiados. Las especies identificadas fueron: Blastocystis spp. 47,3% y 15,4%, Entamoeba coli 21% y 15,4%, Endolimax nana 13% y 53,8%, Complejo Entamoeba 10,5% y 15,4%, Giardia intestinalis 5,2% y 0%, y Entamoeba hartmanni 2,6% y 0% en el grupo muestra y grupo control, respectivamente. No se detectó Strongyloides stercoralis ni otros helmintos intestinales, en los individuos estudiados. Blastocystis spp. fue el más frecuente en los pacientes seropositivos (diferencia estadísticamente significativa) que en el grupo control, lo que pudiese relacionarse con una mayor persistencia de este cromista en pacientes coinfectados con HTLV-I/II. Se puede concluir que el estatus serológico del individuo HTLV-I/II positivo parece no influir en la presencia o adquisición de parásitos intestinales.
Prevalence of intestinal parasites in seropositive and seronegative to HTLV I/II viruses
The prevalence of intestinal parasites in individuals seropositive for the HTLV-I/II virus was studied. A total of 75 donors who attended the blood banks of two health institutions in Maracaibo, Venezuela were randomly selected: 50 patients seropositive for HTLV-I/II (study group) and 25 seronegative individuals (control group). The participants in the study were all contacted personally, after which they provided a fecal sample for parasitological diagnosis. The fresh samples were examined using 0.85% physiological saline solution (PSS), Lugols solution for temporary staining and the formalin-ether concentration technique (Ritchie). In addition, samples were cultured on nutrient agar (Arakaki method) to determine the presence of Strongyloides stercoralis larvae. Overall prevalences of 54% intestinal parasites in the study group and 44% in the control group were found. Monoparasitism prevailed among all the individuals studied. The species identified in the study and control groups were: Blastocystis spp. 47.3% and 15.4%, Entamoeba coli 21% and 15.4%, Endolimax nana 13.0% and 53.8%, Entamoeba complex 10.5% and 15.4%, Giardia intestinalis 5.2% and 0%, and Entamoeba hartmanni 2.6% and 0 %, respectively. Strongyloides stercoralis and other intestinal helminths were not detected in the individuals studied. Blastocystis spp. was significantly more common in seropositive patients than in the control group, which could be associated with a greater persistence of this chromista in patients co-infected with HTLV-I / II.It can be concluded that the positive serological status of HTLV-I / II infected individuals does not seem to influence either the presence or acquisition of intestinal parasites.